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ated with a lower total cost (€ 1,562) and a larger health gain (QALYs) at one year 
(0.732) per patient, and dominated the other treatment strategies since more QALYs 
were achieved at a lower total cost. Sensitivity analyses support the robustness of 
the model. ConClusions: The results indicate that escitalopram is the most cost-
effective pharmacological treatment strategy for the Italian health service compared 
with other SSRIs and all SNRIs used in the first-line treatment of MDD.
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objeCtives: Paliperidone palmitate has demonstrated non-inferior efficacy to 
risperidone long acting injectable (LAI) for the treatment of schizophrenia in previ-
ous studies. The objective of this analysis was to assess the cost effectiveness of 
paliperidone palmitate relative to risperidone LAI, based on the cost-utility analysis 
described in the current NICE Guidelines for the Management of Schizophrenia. The 
analysis was undertaken from the perspective of NHS Wales and was submitted to 
the All Wales Medicines Strategy Group for evaluation. Methods: A decision-ana-
lytic Markov model was developed to estimate the cost-utility of paliperidone palmi-
tate relative to risperidone LAI. The model adopted an annual cycle length. Patients 
who entered the model initiated either paliperidone palmitate or risperidone LAI 
and could subsequently transition between five health states during each annual 
cycle. AEs associated with each intervention were derived from literature. Utility 
values were derived from a community-based study, using trade-off technique to 
elicit HRQoL for schizophrenia according to frequency of injections. Resource use 
data was sourced from the NICE core model/guidelines, Welsh clinical experts, and 
a UK Delphi panel. Unit costs were derived from the British National Formulary, NHS 
reference costs, and the Personal Social Services Research Unit reports. Costs and 
outcomes were evaluated over a 10-year horizon, and discounted at 3.5%. Results 
were presented as incremental costs/QALY. Uncertainty was addressed via deter-
ministic and probabilistic sensitivity analyses. Results: The base case analyses 
demonstrated that paliperidone palmitate would incur lower costs (-£3,773) and 
generate more quality adjusted life years (QALYs) (+0.13) than risperidone LAI. This 
indicated that paliperidone palmitate ‘dominated’ risperidone LAI. Extensive sce-
nario/sensitivity analyses confirmed the robustness of the results ConClusions: 
Compared with risperidone LAI, paliperidone palmitate is a cost-effective therapy 
for the treatment of schizophrenia in adult patients in NHS Wales.
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objeCtives: Major depressive disorder (MDD) causes a massive health and eco-
nomic burden for societies worldwide. Cognitive behavioural therapy (CBT) is an 
inherent part of the treatment of MDD and is recommended for children, adoles-
cents and adults. Cost-Utility-Analysis (CUA) is an important instrument to sup-
port decision-making on resource allocation and health policy as it permits the 
comparison of interventions for different diseases. The objective of our study was 
to systematically review CUAs related to CBT in the treatment of patients suffering 
from MDD. Methods: We conducted a systematic literature search in MEDLINE, 
EMBASE, PsycINFO and NHSEED. We included all original studies reporting CUA of 
CBT for patients suffering from MDD. Cost data were inflated to the year 2011 and 
converted into US-$ using purchasing power parities (US-$ PPP) to ensure compa-
rability of the data. Quality assessment of the studies was performed by means of 
a standardised quality checklist. Results: We identified 22 CUAs. The methodo-
logical quality was fair. Two studies considered a lifetime horizon. The mean time 
horizon of the remaining studies was 19.2 months (SD = 12.6). In most instances 
individual and group CBT as well as CBT for maintenance showed acceptable cost-
utility ratios (ICER < 50.000 US-$-PPP / QALY). The results of CUAs of CBT provided 
for children and adolescents or by computer were inconsistent. In comparison 
to medication CBT tends to be more cost effective as stand-alone therapy and in 
combination with medication. ConClusions: Individual and group CBT is a cost 
effective treatment for MDD. Further research to determine the cost effectiveness 
of computerized CBT and of CBT for specific populations like children, adolescents 
or the elderly is required. Furthermore there is a need for long term evidence of 
cost effectiveness of CBT.
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objeCtives: This study compared health care resource utilization (HRU) and costs 
among children/adolescents with attention deficit/hyperactivity disorder (ADHD) 
in Germany who initiated treatment with atomoxetine (ATX) or long-acting meth-
ylphenidate (LA-MPH). Methods: A retrospective propensity score matched cohort 
analysis was conducted using the IMS electronic medical record database compris-
ing > 15 million patient records from ~3,000 German physicians. Included patients 
were aged 6-17 years, with a first (index) ATX or LA-MPH prescription in 2006-2010; 
≥ 1 ADHD diagnoses 12-month before (pre-index) and after (post-index) index; and 
≥ 1 index medication prescription post-index. Patients in the ATX and LA-MPH 
PMH42
Cost-Utility analysis of lisdExaMfEtaMinE in tHE trEatMEnt of 
CHildrEn and adolEsCEnts WitH attEntion-dEfiCit/HyPEraCtivity 
disordEr in tHE UnitEd KingdoM
Zimovetz E.1, Beard S.M.2, Hodgkins P.3, Bischof M.4, Mauskopf J.A.5, Setyawan J.3
1RTI Health Solutions, Manchester, UK, 2BresMed Health Solutions Ltd., Sheffield, UK, 3Shire, 
Wayne, PA, USA, 4Shire, Eysins, Switzerland, 5RTI Health Solutions, Research Triangle Park, NC, 
USA
objeCtives: An economic analysis was conducted from the United Kingdom’s 
(UK’s) National Health Service (NHS) perspective to evaluate the cost-effectiveness 
of lisdexamfetamine (LDX) versus atomoxetine (ATX) in treating children and 
adolescents with attention-deficit/hyperactivity disorder (ADHD) who have had 
an inadequate response to methylphenidate (MPH). Methods: A 1-year proba-
bilistic decision-analytic model with a Markov structure of nested decision trees 
was constructed. Health states included “response”, “non-response”, and “unable 
to tolerate”. Key model assumptions were adapted from a technology assessment 
for ADHD products by the National Institute for Health and Care Excellence. The 
analysis used clinical data from a head-to-head randomized controlled trial in inad-
equate responders to MPH. Response to treatment was defined as a score of 1 (much 
improved) or 2 (improved) on the Clinical Global Impression-Improvement scale. 
Tolerability was assessed by rates of discontinuation due to adverse events. Utility 
weights were identified via a systematic literature review. Health care resource use 
estimates for responders and non-responders were obtained via a survey of UK spe-
cialists. Unit costs from national sources were applied to estimate the correspond-
ing health-state costs. Daily drug costs were based on mean doses reported in the 
trial. One-way and probabilistic sensitivity analyses were performed. Results: The 
comparison of LDX and ATX, using head-to-head data, resulted in an incremental 
cost-effectiveness ratio (ICER) of £1,802 per quality-adjusted life year (QALY). At a 
willingness to pay of £20,000 per QALY, LDX had an 86% probability of being cost-
effective compared with ATX. In 38% of sensitivity analysis runs, LDX was a domi-
nant strategy over ATX. The model was slightly sensitive to changes in assumptions 
about drug costing and to lengthening the titration period for ATX. ConClusions: 
From the perspective of the UK NHS, LDX provides a cost-effective treatment option 
for children and adolescents with ADHD who are inadequate responders to MPH.
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objeCtives: The cost-effectiveness of second-generation antipsychotic drugs 
is well established in the treatment of patients experiencing a manic episode 
associated with bipolar I disorder. However, no studies demonstrating the value of 
these drugs in patients with mixed episodes according to DSM-IV have so far been 
undertaken. The aim of this study was to assess the cost-effectiveness of asenapine 
versus olanzapine in the treatment of this costly subgroup of patients. Methods: 
A 9-week acute phase model was developed, during which patients receive up to 
three lines of treatment: asenapine or olanzapine alone, then adjunctive valproate, 
and finally a switch to adjunctive lithium. Patients can respond during any 3-week 
period and non-responders move to the next treatment in the sequence. Efficacy of 
asenapine (46.3%) and olanzapine (37.5%) was informed by a post-hoc analysis of 
two short-term clinical trials, where response was measured as a composite YMRS 
and MADRS endpoint. Following initial treatment, patients entered a 5-year main-
tenance Markov model during which they faced probabilities of treatment discon-
tinuation, recurrent manic, mixed and depressive symptoms and death. Direct costs 
(year 2012-13 values), including drug, monitoring costs and resource use related to 
bipolar disorder and selected adverse events, were assessed from a UK NHS per-
spective. Benefits were measured as quality-adjusted life years (QALYs). Results: 
For patients with a mixed episode, asenapine was a more effective and less costly 
treatment strategy compared with olanzapine over a 5-year period. Greater health 
benefits and cost savings were driven by earlier response to asenapine treatment 
during the acute phase and were well maintained during longer-term follow-up. 
These results were robust to changes in key parameters including short and longer-
term efficacy, unit cost and utility values. ConClusions: Compared with olanzap-
ine, results of this analysis suggest that asenapine generates greater health benefits 
at lower cost in the treatment of patients experiencing mixed episodes associated 
with bipolar I disorder.
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objeCtives: To assess the cost-effectiveness (€ per quality-adjusted life year [QALY]) 
of all Selective serotonin reuptake inhibitors (SSRIs) and all Serotonin-norepinephrine 
reuptake inhibitors (SNRIs) for the treatment of Major Depressive Disorder (MDD) in 
Italy. Methods: A decision analytic model was adapted from the Swedish Dental 
and Pharmaceutical Benefits agency model to reflect current clinical practice in the 
treatment of MDD in the largest Italian regions. This adaptation was possible thanks 
to the collaboration of an expert panel of Italian psychiatrists and health economists. 
The model evaluated patients with a first diagnosis of MDD and initiating an SSRI 
or an SNRI for the first time. The time horizon was 12 months. Efficacy and utility 
data for the model were retrieved from the literature and validated by the expert 
panel. Local data were considered for resource utilization and for treatment costs 
based on each regional health service perspective. Population-weighted regional 
data were used to define a national model. Scenario simulations, one-way sensitiv-
ity analyses, and Monte Carlo simulations were performed to test the robustness of 
the model. Results: The base case analysis showed that escitalopram was associ-
